We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Mpro

News List

Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern firstwordpharma
August 27, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A&M University System ("TAMUS") of its exercise of the option to an exclusive license for the global development and commercialization of highly potent
Anixa, OntoChem Announce Identification of Additional Covid-19 Compounds americanpharmaceuticalreview
August 18, 2020
Anixa Biosciences announced that the company and its partner, OntoChem, have identified additional candidates through their in silico screening study.